Click here to subscribe to the Multiple Sclerosis News Today Newsletter! 5 (2)
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treatment with Tysabri (natalizumab) can improve mental and social health in people with multiple sclerosis (MS), according to new data presented at the 2021 virtual American Academy of Neurology annual meeting (AANAM).
Data presented at AANAM also indicate that less frequent dosing of Tysabri can reduce the risk of rare brain infections, while still lowering MS disease activity.
Tysabri, by Biogen, is an approved treatment for relapsing forms of MS, and works by blocking inflammatory immune cells from getting into the brain. In clinical trials, Tysabri has been demonstrated to lower the rate of MS relapses and to ease symptoms. Treatment with Tysabri also has been associated wi
email article
While the Alzheimer s field waits for the FDA s decision on the investigational treatment aducanumab, drug developer Biogen has provided details and endpoints of EMBARK, the drug s ongoing phase IIIb redosing study.
Aducanumab, a monoclonal antibody that selectively binds to aggregated forms of amyloid beta, has raised considerable controversy in the wake of findings from two identical phase III studies, EMERGE and ENGAGE. The trials were terminated in March 2019 when a futility analysis determined aducanumab was unlikely to outperform placebo at completion. In October 2019, Biogen reversed its position, saying a review of previously unavailable data showed the drug actually reduced cognitive decline in EMERGE, but not in ENGAGE.
email article
Patients diagnosed with idiopathic hypersomnia characterized by excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia appeared to benefit from a novel oxybate treatment with 92% less sodium than sodium oxybate (Xyrem), a researcher reported.
Significant worsening was observed in Epworth Sleepiness Scale (ESS) scores for patients receiving placebo compared with lower-sodium oxybate (Xywav), for a mean difference of -6.51 (95% CI -7.99 to -5.03,
P
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care, new research shows.
The findings indicate that people with health conditions like MS may be at increased risk of health problems as temperatures rise due to climate change, according to Holly Elser, PhD, an epidemiologist and medical student at Stanford University.
The idea for this study, according to Elser, originated with a MS patient during a routine medical appointment: “[the patient] mentioned off-handedly, ‘you know, my MS gets really bad when it’s hot outside, ” said Elser.
EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.